Abstract
At present, nucleoside analogs have become the primary choice in the treatment of HBV infection, which are able to inhibit the replication of HBV effectively. Nevertheless, long-term therapy of nucleoside analogs leads to a resistant mutants. The resistance mechanisms of nucleoside analogs in the treatment of HBV infection are reviewed in this article. Key words: Hepatitis B virus; Nucleos(t)ide analogs; Resistance mechanism
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
